FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022052477> ?p ?o ?g. }

• W2022052477 endingPage "763" @default.
• W2022052477 startingPage "755" @default.
• W2022052477 abstract "The aim of the present study was to analyze the molecular mechanisms involved in blocking the signaling pathway and the effects of this on the progression of prostate cancer (CaP) cells in vitro. LNCaP human CaP cell line was stimulated with interleukin‑6 (IL‑6) in the presence/absence of Janus kinase (JAK) 2 (AG490), signal transducer and activator of transcription 3 [(STAT3) S3I‑201] inhibitors and tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL). Cytotoxic activity, the activation of phosphorylated (p)‑STAT3 protein, caspase (CASP) 3 activity at protein level, vascular endothelial growth factor (VEGF) A, VEGFC, vascular endothelial growth factor receptor 2, STAT3, matrix metalloproteinase-2, myeloid cell leukemia sequence 1 (MCL‑1), CASP8 and CASP9 messenger RNA (mRNA) levels were determined. Morphology and apoptosis were confirmed by DAPI staining and terminal deoxynucleotidyl transferase‑mediated dUTP nick‑end labeling (TUNEL) assay. IL‑6 rapidly induced the phosphorylation of STAT3 in a dose‑ and time‑dependent manner with a peak expression at 3 h at a concentration of 25 ng/ml. In addition, AG490 (50 µM) and S3I‑201 (300 µM) inhibited STAT3 activation. Western blotting results revealed that p‑STAT3 protein expression decreased significantly with AG490 and S3I‑201 treatment in LNCaP cells. AG490 and S3I‑201 induced the downregulation of VEGFA, MCL‑1 and STAT3 and the upregulation of CASP8 and CASP9 mRNA transcription levels. In addition, the inhibitors increased the level of CASP3 protein. Combinations of AG490‑ and S3I‑201‑TRAIL did not result in an increase in this effect. Parallel results were found by DAPI staining and TUNEL assay. To the best of our knowledge, this is the first study to investigate the possible clinical use of AG490 or S3I‑201, together with the reduced use of chemotherapeutic agents with high cytotoxicity, for their ability to exert an apoptotic effect, targeting the JAK/STAT3 pathway." @default.
• W2022052477 created "2016-06-24" @default.
• W2022052477 creator A5011520878 @default.
• W2022052477 creator A5011921533 @default.
• W2022052477 creator A5058611358 @default.
• W2022052477 creator A5071364904 @default.
• W2022052477 creator A5077288881 @default.
• W2022052477 creator A5077823160 @default.
• W2022052477 creator A5091409729 @default.
• W2022052477 date "2014-01-14" @default.
• W2022052477 modified "2023-10-06" @default.
• W2022052477 title "Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro" @default.
• W2022052477 cites W1492452090 @default.
• W2022052477 cites W1507176085 @default.
• W2022052477 cites W1964647119 @default.
• W2022052477 cites W1968720160 @default.
• W2022052477 cites W1971113195 @default.
• W2022052477 cites W1973009607 @default.
• W2022052477 cites W1977818137 @default.
• W2022052477 cites W1981896461 @default.
• W2022052477 cites W1987388371 @default.
• W2022052477 cites W1990461493 @default.
• W2022052477 cites W2000792691 @default.
• W2022052477 cites W2006382528 @default.
• W2022052477 cites W2007840001 @default.
• W2022052477 cites W2007897471 @default.
• W2022052477 cites W2008590114 @default.
• W2022052477 cites W2013430397 @default.
• W2022052477 cites W2014763555 @default.
• W2022052477 cites W2015109149 @default.
• W2022052477 cites W2029638319 @default.
• W2022052477 cites W2035173779 @default.
• W2022052477 cites W2041204531 @default.
• W2022052477 cites W2048601897 @default.
• W2022052477 cites W2053298425 @default.
• W2022052477 cites W2063143301 @default.
• W2022052477 cites W2065647535 @default.
• W2022052477 cites W2074817574 @default.
• W2022052477 cites W2079603698 @default.
• W2022052477 cites W2085233944 @default.
• W2022052477 cites W2089789813 @default.
• W2022052477 cites W2090558145 @default.
• W2022052477 cites W2099249565 @default.
• W2022052477 cites W2101061199 @default.
• W2022052477 cites W2106588382 @default.
• W2022052477 cites W2107569591 @default.
• W2022052477 cites W2116628300 @default.
• W2022052477 cites W2120286360 @default.
• W2022052477 cites W2129788206 @default.
• W2022052477 cites W2129927432 @default.
• W2022052477 cites W2130352141 @default.
• W2022052477 cites W2130644579 @default.
• W2022052477 cites W2133059565 @default.
• W2022052477 cites W2138578836 @default.
• W2022052477 cites W2138640102 @default.
• W2022052477 cites W2139520473 @default.
• W2022052477 cites W2141235890 @default.
• W2022052477 cites W2143956889 @default.
• W2022052477 cites W2144888252 @default.
• W2022052477 cites W2148416479 @default.
• W2022052477 cites W2161045275 @default.
• W2022052477 cites W2162653187 @default.
• W2022052477 cites W2170476872 @default.
• W2022052477 cites W2318269950 @default.
• W2022052477 doi "https://doi.org/10.3892/ol.2014.1795" @default.
• W2022052477 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3919920" @default.
• W2022052477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24520293" @default.
• W2022052477 hasPublicationYear "2014" @default.
• W2022052477 type Work @default.
• W2022052477 sameAs 2022052477 @default.
• W2022052477 citedByCount "38" @default.
• W2022052477 countsByYear W20220524772014 @default.
• W2022052477 countsByYear W20220524772015 @default.
• W2022052477 countsByYear W20220524772016 @default.
• W2022052477 countsByYear W20220524772017 @default.
• W2022052477 countsByYear W20220524772018 @default.
• W2022052477 countsByYear W20220524772019 @default.
• W2022052477 countsByYear W20220524772020 @default.
• W2022052477 countsByYear W20220524772021 @default.
• W2022052477 countsByYear W20220524772022 @default.
• W2022052477 countsByYear W20220524772023 @default.
• W2022052477 crossrefType "journal-article" @default.
• W2022052477 hasAuthorship W2022052477A5011520878 @default.
• W2022052477 hasAuthorship W2022052477A5011921533 @default.
• W2022052477 hasAuthorship W2022052477A5058611358 @default.
• W2022052477 hasAuthorship W2022052477A5071364904 @default.
• W2022052477 hasAuthorship W2022052477A5077288881 @default.
• W2022052477 hasAuthorship W2022052477A5077823160 @default.
• W2022052477 hasAuthorship W2022052477A5091409729 @default.
• W2022052477 hasBestOaLocation W20220524771 @default.
• W2022052477 hasConcept C121608353 @default.
• W2022052477 hasConcept C167734588 @default.
• W2022052477 hasConcept C171958077 @default.
• W2022052477 hasConcept C185592680 @default.
• W2022052477 hasConcept C2777025900 @default.
• W2022052477 hasConcept C2778923194 @default.
• W2022052477 hasConcept C2779723316 @default.
• W2022052477 hasConcept C2780192828 @default.

• next